Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Equity (2019 - 2025)

Keros Therapeutics' Return on Equity history spans 7 years, with the latest figure at 0.17% for Q4 2025.

  • For Q4 2025, Return on Equity rose 51.0% year-over-year to 0.17%; the TTM value through Dec 2025 reached 0.17%, up 51.0%, while the annual FY2025 figure was 0.2%, 61.0% up from the prior year.
  • Return on Equity reached 0.17% in Q4 2025 per KROS's latest filing, up from 0.09% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.17% in Q4 2025 to a low of 0.54% in Q4 2023.
  • Average Return on Equity over 5 years is 0.27%, with a median of 0.35% recorded in 2022.
  • Peak YoY movement for Return on Equity: crashed -114bps in 2021, then surged 51bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.25% in 2021, then plummeted by -59bps to 0.4% in 2022, then crashed by -34bps to 0.54% in 2023, then skyrocketed by 37bps to 0.34% in 2024, then soared by 151bps to 0.17% in 2025.
  • Per Business Quant, the three most recent readings for KROS's Return on Equity are 0.17% (Q4 2025), 0.09% (Q3 2025), and 0.03% (Q2 2025).